CorMedix shares are trading higher after Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $13 price target.
Portfolio Pulse from Benzinga Newsdesk
CorMedix shares rose after Rodman & Renshaw initiated coverage with a Buy rating and a $13 price target.
August 26, 2024 | 3:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
CorMedix shares increased following Rodman & Renshaw's initiation of coverage with a Buy rating and a $13 price target.
The initiation of coverage by Rodman & Renshaw with a Buy rating and a $13 price target is a positive signal for investors, likely leading to increased buying interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100